PepGen closed at $2.45 on Nov 4, down 0.41%, 65.8% below its 52-week closing high. Volume of 1.8M shares was 1.82× its 20-day average (above normal).
Split-adjusted performance: +6.1% over one month, +32.8% over six months, -45.9% over one year.
Short interest was 3.8M shares at the Oct 15 settlement, down 10.0% from the prior report (9.6% of float, 5.3 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| PEPGPepGen | $2.45 | −0.41% | +32.8% | — | — | — | $169.7M | |
| SIONSionna Therapeutics | $3.73 | +2.19% | −91.4% | — | — | — | $168.6M | Compare |
| ORMPOramed Pharmaceuticals | $4.13 | +3.25% | +5.4% | — | — | 1.0 | $171.8M | Compare |
| INOInovio Pharmaceuticals | $1.62 | −2.41% | +30.6% | — | — | — | $167.5M | Compare |
| ZNTLZentalis Pharmaceuticals | $1.76 | −1.12% | −57.9% | — | — | — | $166.6M | Compare |
| ANTXAN2 Therapeutics | $4.25 | +1.67% | −8.6% | — | — | — | $160.4M | Compare |
| WHWKWhitehawk Therapeutics | $3.17 | +2.26% | −23.6% | — | — | — | $180.7M | Compare |
| BBOTBridgeBio Oncology Therapeutics | $2.30 | −0.86% | −72.4% | — | — | — | $184.4M | Compare |
| ALXOALX Oncology Holdings | $1.36 | +5.43% | −34.9% | — | — | — | $188.1M | Compare |
No recent articles focused on PepGen. 1 articles mention it in passing.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
